Show simple item record

dc.contributor.authorAjjan, RA
dc.contributor.authorKietsiriroje, N
dc.contributor.authorBadimon, L
dc.contributor.authorGorog, Diana
dc.contributor.authorAngiolillo, Dominick J.
dc.contributor.authorRussel, D
dc.contributor.authorRocca, Bianca
dc.contributor.authorStorey, Robert F.
dc.date.accessioned2021-06-10T16:34:47Z
dc.date.available2021-06-10T16:34:47Z
dc.date.issued2021-03-25
dc.identifier.citationAjjan , RA , Kietsiriroje , N , Badimon , L , Gorog , D , Angiolillo , D J , Russel , D , Rocca , B & Storey , R F 2021 , ' Antithrombotic therapy in diabetes: Which, when, and for how long? ' , European Heart Journal . https://doi.org/10.1093/eurheartj/ehab128
dc.identifier.issn0195-668X
dc.identifier.otherPURE: 24591151
dc.identifier.otherPURE UUID: db15cb6b-8a12-4420-b52b-63d82c3104f5
dc.identifier.urihttp://hdl.handle.net/2299/24576
dc.description© The Author(s) 2021. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/)
dc.description.abstractCardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis secondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk remain largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM. The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in different clinical scenarios including coronary, cerebrovascular and peripheral artery disease. Antiplatelet therapy combinations as well as combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long-term, including management of individuals with sinus rhythm and those with atrial fibrillation. The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasised, in addition to the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This review provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in knowledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.en
dc.format.extent25
dc.language.isoeng
dc.relation.ispartofEuropean Heart Journal
dc.titleAntithrombotic therapy in diabetes: Which, when, and for how long?en
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.relation.school
dcterms.dateAccepted2021-03-25
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.1093/eurheartj/ehab128
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record